GET DAILY SIGNALSWhy Is Anika Therapeutics (ANIK) Stock Down -21.21% Today?
Key Takeaways
- ANIK shares fell approximately 21.21% to $15.23, down from a prior close of $19.33.
- The primary catalyst was the U.S. Food and Drug Administration's decision that the Hyalofast premarket approval application is "not approvable," primarily on clinical data.
- Secondary pressure came from a cut to commercial-channel growth guidance and a sequential decline in gross margin.
- Offsetting positives—including a top-line revenue beat, a raised total-company guidance floor, and a new 10-year Hyvisc agreement—were not enough to support the shares.
- The broader context: ANIK had more than doubled over the prior year, leaving it vulnerable to a regulatory setback.
- Traders are now watching the regulatory path forward for Hyalofast, the Cingal NDA timeline, and fourth-quarter execution.
- For deeper data on this name, explore Price Targets, Earnings, and Forecast pages for ANIK.
- To see how AI trading systems are positioning across the market, explore Trending AI Robots.
Opening Summary
Anika Therapeutics, Inc. (ANIK), a Bedford, Massachusetts-based joint preservation company focused on early-intervention orthopedics and hyaluronic acid (HA) innovations, saw its shares plunge sharply on Friday. The stock fell roughly 21.21% to $15.23, compared with a prior-session close of $19.33, after the company reported third-quarter 2026 results and disclosed that the FDA had deemed its Hyalofast cartilage-repair application not approvable. The decline reflects a market reaction that centered on a regulatory setback and softer forward guidance, overshadowing a headline revenue beat and improved profitability metrics.
FDA "Not Approvable" Decision on Hyalofast
The dominant catalyst behind the sell-off was regulatory. Anika disclosed that, in October, it received formal notification from the FDA that the premarket approval (PMA) application for Hyalofast—a resorbable scaffold used for single-stage cartilage regeneration—is "not approvable," based primarily on the clinical data included in the submission. The company said it continues to believe in Hyalofast's U.S. potential and is assessing regulatory pathways, including discussions with the agency about additional clinical evidence. However, for investors, the decision removes a key near-term growth catalyst and delays a meaningful U.S. revenue opportunity that had been a central part of the bullish thesis.
Third-Quarter Results and Guidance
The earnings release itself was mixed. Total revenue rose 10% year over year to $30.6 million, modestly ahead of consensus, driven by 17% growth in the commercial channel to a record $14.0 million and 5% OEM growth to $16.6 million. Adjusted net income was $3.9 million, or $0.29 per diluted share, while the GAAP loss from continuing operations narrowed to $0.02 per share. Gross margin improved to 62% from 56% a year earlier, but slipped sequentially from 65% in the second quarter on product mix.
The more concerning signals came from guidance. Anika cut its 2026 commercial-channel growth outlook to 9%–13% from 12%–18%, citing softer U.S. elective surgery volumes and Integrity running below plan. While it raised the lower end of total-company revenue growth guidance to 6%–10% and lifted its adjusted EBITDA margin outlook to 15%–17%, much of that upgrade came from the slower-growth OEM channel. The mix shift, combined with the Hyalofast regulatory news, weighed on sentiment.
Market Context and Trading Activity
The decline was accompanied by elevated trading activity, consistent with a sharp earnings-driven repricing in a small-cap name. ANIK had been a strong performer over the prior year, gaining more than 100%, which left the stock priced for pipeline execution and continued margin expansion. The FDA setback therefore triggered a pronounced de-rating as investors recalibrated the growth outlook. The move reflected company-specific news rather than broad-market weakness, as the sell-off was concentrated in the stock's regulatory and guidance outlook.
What Comes Next for ANIK
Looking ahead, investors will focus on the company's regulatory strategy for Hyalofast and whether additional clinical evidence can support a future approval. The Cingal NDA timeline—now targeted before year-end 2027—remains another key catalyst, as does the execution of the newly signed 10-year Hyvisc agreement with Boehringer Ingelheim. Fourth-quarter execution, U.S. elective procedure trends, and the sustainability of gross-margin improvement will also be closely watched. Risks include further regulatory delays, pricing pressure in the U.S. osteoarthritis market, and the possibility that commercial-channel growth continues to underperform prior expectations.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. Only the strongest performers are featured in this section, giving traders a focused view of where AI systems are finding opportunity. Explore the Trending AI Robots page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ANIK's RSI Indicator descending into oversold zone
The RSI Oscillator for ANIK moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANIK advanced for three days, in 168 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
ANIK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 119 of 164 cases where ANIK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANIK as a result. In 76 of 114 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for ANIK turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 32 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
ANIK moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ANIK crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANIK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.418) is normal, around the industry mean (7.271). P/E Ratio (-53.889) is within average values for comparable stocks, (0.479). Projected Growth (PEG Ratio) (2.177) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (2.401) is also within normal values, averaging (181.047).
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. ANIK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANIK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of commercializes therapeutic products for tissue protection, healing and repair
Industry PharmaceuticalsGeneric
Advertisement